期刊
HUMAN VACCINES & IMMUNOTHERAPEUTICS
卷 9, 期 1, 页码 122-124出版社
TAYLOR & FRANCIS INC
DOI: 10.4161/hv.22317
关键词
live attenuated; pandemic H1N1 vaccine; post-marketing surveillance
资金
- Serum Institute of India Ltd
A live attenuated pandemic H1N1 influenza vaccine was developed in India. A post marketing surveillance was conducted retrospectively in healthy individuals (>= 3 y) who were vaccinated intranasally around one year before. After consent, the subjects recorded adverse events developing within 42 d. Among 7,565 individuals (3-85 y), a total of 81 solicited adverse reactions (1%) were reported in 49 subjects (0.65%). The reactions included mild to moderate respiratory symptoms. No H1N1 case was encountered during one year post vaccination. The data show the safety of the live attenuated influenza vaccine platform developed in India.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据